CClinicalTrials.gg
CompletedNCT05245526Updated Mar 20, 2023Results posted

SpO2 Accuracy of Noninvasive Disposable Pulse Oximeter Sensor

An interventional study of STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS in Healthy and Hypoxia, sponsored by Stryker Sustainability Solutions. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-20.

Sponsored by Stryker Sustainability Solutions · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this clinical study is to validate the SpO2 accuracy of the Stryker Sustainability Solutions pulse oximetry sensors during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. The end goal is to provide supporting documentation for the SpO2 accuracy validation of the reprocessed sensors.

Read the detailed description

In this study, the level of oxygen within the blood will be reduced in a controlled manner by reducing the concentration of oxygen the participant breathes. The accuracy of a noninvasive pulse oximeter sensor will be assessed by comparison to the oxygen saturation measurements from a laboratory blood gas analyzer.

It is required that the Accuracy Root Mean Square (ARMS) performance of the Stryker pulse oximetry sensors will meet a specification of +/-3% or better in non-motion conditions for the range of 70 - 100% SaO2 (typically, saturation is determined once with air breathing and then at one of 3 levels, e.g. 95%, 85%, and 75% saturation for about 30-60 seconds at each level), thereby demonstrating an acceptable SpO2 accuracy performance specification.

02

Conditions studied

  • Healthy
  • Hypoxia

Browse trials for

03

In context

Hypoxia

1,231 studies on the registry are indexed under Hypoxia; 241 are open to participants now.

This study's enrollment of 12 is below the median of 45 across 853 interventional studies indexed under Hypoxia.

Browse Hypoxia studies →

Lead sponsor

Stryker Sustainability Solutions is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Good general health with no evidence of pre-existing medical problems
  • Fluent in both written and spoken English
  • Must be able to review informed consent and is willing to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • Obesity (BMI >30)
  • Known history of heart disease, lung disease, kidney or liver disease
  • Prior diagnosis of asthma, sleep apnea, or use of CPAP
  • Diabetes
  • Clotting disorder
  • Hemoglobinopathy or history of anemia that in the opinion of the investigators would make them unsuitable for study participation
  • Any serious systemic illness
  • Current smoker
  • Any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigator would interfere with the sensors working correctly
  • History of fainting or vasovagal response
  • History of sensitivity to local anesthesia
  • Prior diagnosis of Raynaud's disease
  • Unacceptable collateral circulation based on exam by investigators (Allen's test)
  • Pregnant, lactating, or trying to get pregnant
  • Unable or unwilling to provide informed consent, or unable or unwilling to comply with study procedures
  • Any other condition which in the opinion of the investigators would make them unsuitable for the study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Healthy adult participants

    All participants are enrolled in the test group and receive the noninvasive adhesive reprocessed pulse oximeter sensors.

    Device: STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS

Interventions

  • DeviceSTRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS

    Reprocessed noninvasive pulse oximeter sensors.

06

What researchers measure

Primary outcomes

  1. Accuracy of Sensor by Arms Calculation

    Percentage of SpO2 (oxygen saturation by pulse oximetry) measured by the Reprocessed Oximeter pulse oximetry sensors during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. Accuracy root mean square (ARMS) between measured SpO2 and reference SaO2 (arterial oxygen saturation) must meet the 3% specification for each reprocessed pulse oximetry sensor style. Accuracy will be determined by comparing the noninvasive blood oxygen saturation measurement of the pulse oximeter to that obtained from a blood sample and calculating the arithmetic root mean square error (Arms) value. Standard deviation of the differences is computed as the precision. Square root of the sum of the squares of bias and precision is computed as the Arms Error value.

    Time frame: 1-2 hours

07

Results

Posted Mar 20, 2023

Participant flow

Participant flow — Overall Study
MilestoneHealthy Adult Participants
Started12
Completed12
Not completed0

Outcome measures

PrimaryAccuracy of Sensor by Arms Calculation

Percentage of SpO2 (oxygen saturation by pulse oximetry) measured by the Reprocessed Oximeter pulse oximetry sensors during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. Accuracy root mean square (ARMS) between measured SpO2 and reference SaO2 (arterial oxygen saturation) must meet the 3% specification for each reprocessed pulse oximetry sensor style. Accuracy will be determined by comparing the noninvasive blood oxygen saturation measurement of the pulse oximeter to that obtained from a blood sample and calculating the arithmetic root mean square error (Arms) value. Standard deviation of the differences is computed as the precision. Square root of the sum of the squares of bias and precision is computed as the Arms Error value.

Time frame:
1-2 hours
Reported as:
Number · Root Mean Square Error (%)
Accuracy of Sensor by Arms Calculation
Root Mean Square Error (%)Device 1: Reprocessed Masimo RD Set Pulse Oximeter Sensor, 4000 AdtDevice 2: Reprocessed Masimo RD Set Pulse Oximeter Sensor, 4003 Neo
Accuracy of Sensor by Arms Calculation2.042.11

Adverse events

Collected over 2 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Device 10/12 (0%)0/12 (0%)0/12 (0%)
Device 20/12 (0%)0/12 (0%)0/12 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Healthy Adult Participants
<=18 years0
Between 18 and 65 years12
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Healthy Adult Participants
Female7
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Healthy Adult Participants
Caucasian2
Black or African American3
Asian4
Hispanic1
Multiethnic2
Region of Enrollment
Region of Enrollment(participants)Healthy Adult Participants
United States12
08

Study locations

1 site
  • UCSF Hypoxia Research Laboratory
    San Francisco, California 94133, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 19, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — Data to be used by Sponsor only.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05245526
Lead sponsor
Stryker Sustainability Solutions
Collaborators
University of California, San Francisco
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Jan 19, 2022
Primary completion
Jan 20, 2022
Completion
Jan 20, 2022
Results posted
Mar 20, 2023
Last update
Mar 20, 2023

Study contacts

Philip E Bickler, MD, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion